1 hr ago
Rothschild Says Moderna Is Overvalued After Cancer Vaccine Surge
Moderna is a company whose stock price rose quickly recently.
The rise came after positive news about its experimental cancer vaccine.
Rothschild & Co Redburn, an investment research firm, thinks the stock has risen too much.
It called Moderna’s shares “considerably overvalued.”
Overvalued means the firm believes the shares cost more than they are currently worth.
The vaccine is still experimental.
The article does not say whether the vaccine will eventually be approved.
It also does not give a specific price target for Moderna’s shares.
Moderna shares recently surged following success involving its experimental cancer vaccine.
Rothschild & Co Redburn said Moderna’s shares are now “considerably overvalued.”
The article links the stock’s recent rise to optimism around the cancer vaccine.
The cancer vaccine remains experimental, according to the report.
The report does not provide a specific price target or valuation estimate.
- Who
- Moderna and Rothschild & Co Redburn.
- What
- Rothschild & Co Redburn said Moderna’s shares are considerably overvalued after a recent surge.
- Where
- When
- Recently; the article does not provide a specific date.
- Why
- The share surge followed reported success involving Moderna’s experimental cancer vaccine.
Key facts
- Company
- Moderna
- Analyst
- Rothschild & Co Redburn
- Assessment
- Moderna shares are “considerably overvalued,” according to the firm.
- Recent market move
- Moderna shares have recently been on a tear.
- Reported catalyst
- Success involving Moderna’s experimental cancer vaccine.
- Vaccine status
- The cancer vaccine is experimental.
Sources
Related news
Moderna shares surge as melanoma vaccine data sparks rally
Moderna’s Cancer Vaccine Surge Inflicts Billions in Short-Seller Losses
Cancer Vaccine Trial Sends Moderna Shares Soaring 177 Percent
Moderna Shares Surge After Positive Personalized Melanoma Trial Results
Cancer Vaccine Trial Raises Hopes for Treatment Beyond Melanoma
Wall Street Rises as Easing Yields, Moderna Boost Healthcare
Merck and Moderna Vaccine Posts Positive Phase 3 Melanoma Results
